logo

SION

Sionna Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.19 / 10
Netural

SION's fundamental score is 4.2/10, reflecting a neutral stance. Key strengths include a healthy interest-coverage ratio (15.48) and positive asset-to-market value, while a high days-sales-outstanding (72.55) drags performance. Revenue growth is impressive YoY, yet mixed profitability and cash-flow metrics prevent a higher rating. Overall, the company shows promise but needs tighter working-capital management.

Fundamental(4.19)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight18.76%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.60%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.06%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight14.96%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight14.97%
1M Return8.45%
PB-ROE
Value2.78
Score2/3
Weight18.65%
1M Return9.14%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.62%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight19.29%
1M Return10.15%
Cash-MV
Value-0.07
Score2/3
Weight14.71%
1M Return8.41%
Is SION undervalued or overvalued?
  • SION scores 4.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -22.46% ROE, 0.00% net margin, -21.02 P/E ratio, 4.96 P/B ratio, and 72.43% earnings growth, these metrics solidify its Netural investment rating.